Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.
Centre for Addiction and Mental Health (CAMH), Toronto, ON M5T 1R8, Canada.
Int J Mol Sci. 2021 Jan 21;22(3):1047. doi: 10.3390/ijms22031047.
Altered activity of fatty acid amide hydrolase (FAAH), an enzyme of the endocannabinoid system, has been implicated in several neuropsychiatric disorders, including major depressive disorder (MDD). It is speculated that increased brain FAAH expression is correlated with increased depressive symptoms. The aim of this scoping review was to establish the role of FAAH expression in animal models of depression to determine the translational potential of targeting FAAH in clinical studies. A literature search employing multiple databases was performed; all original articles that assessed FAAH expression in animal models of depression were considered. Of the 216 articles that were screened for eligibility, 24 articles met inclusion criteria and were included in this review. Three key findings emerged: (1) FAAH expression is significantly increased in depressive-like phenotypes; (2) genetic knockout or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect; and (3) differences in FAAH expression in depressive-like phenotypes were largely localized to animal prefrontal cortex, hippocampus and striatum. We conclude, based on the animal literature, that a positive relationship can be established between brain FAAH level and expression of depressive symptoms. In summary, we suggest that FAAH is a tractable target for developing novel pharmacotherapies for MDD.
脂肪酸酰胺水解酶(FAAH)活性的改变,作为内源性大麻素系统的一种酶,与多种神经精神疾病有关,包括重度抑郁症(MDD)。据推测,大脑 FAAH 表达的增加与抑郁症状的增加有关。本范围综述的目的是确定 FAAH 表达在抑郁症动物模型中的作用,以确定在临床研究中靶向 FAAH 的转化潜力。采用多个数据库进行了文献检索;所有评估抑郁症动物模型中 FAAH 表达的原始文章均被认为符合纳入标准。在筛选出的 216 篇有资格的文章中,有 24 篇符合纳入标准并被纳入本综述。有三个关键发现:(1)在抑郁样表型中 FAAH 表达显著增加;(2)FAAH 的基因敲除或药理学抑制可有效减轻抑郁样行为,具有剂量依赖性效应;(3)抑郁样表型中 FAAH 表达的差异主要局限于动物前额叶皮层、海马体和纹状体。基于动物文献,我们得出结论,大脑 FAAH 水平与抑郁症状的表达之间可以建立正相关关系。总之,我们认为 FAAH 是开发治疗 MDD 的新型药物疗法的可行靶点。